Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer's disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic Alzheimer’s disease were announced on the company’s website.  […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!